AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.23
+1.21%Aug 6, 2026, 11:00 UTC
Avalo Therapeutics announced its financial results for the second quarter of 2026.
Source:Jun 23, 2026, 00:00 UTC
Avalo Therapeutics appointed Ron Philip as a director, effective June 23, 2026.
Jun 16, 2026, 11:00 UTC
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, for development in hidradenitis suppurativa and other inflammatory disorders.
Source: